Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease. The Company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its programs in atopic dermatitis and targeted orphan indications. For more information visit www.azitrainc.com.
Azitra Inc的外部链接
21 Business Park Dr
US，Connecticut，Branford，06405
Thanks Daniel Levine - check out the discussion at Global Genes's #podcast #RARECast
Travis Whitfill, co-founder and chief operating officer of Azitra Inc, discusses Netherton syndrome, the company’s platform technology for engineering live biotherapeutic products, and why it takes more than simply inserting a gene into a desired bacteria to produce these treatments. Global Genes #RARECast https://lnkd.in/gk9XeCgF
Azitra Inc转发了
Francisco Salva, CEO of Azitra Inc., delves into the innovative strategies employed by the company in treating skin diseases. Azitra leads the way in utilizing engineered living organisms to combat rare conditions such as Netherton syndrome and ichthyosis vulgaris. By leveraging cutting-edge technologies like artificial intelligence, Azitra aims to establish novel benchmarks in dermatological care. Francisco sheds light on Azitra's distinctive approaches, ongoing clinical trials, and the intricacies faced within this specialized domain. ???????? ????????: https://lnkd.in/d4WjsKgV
In case you missed it, last week Azitra Inc COO Travis Whitfill spoke with Zacks Small Cap Research' John Vandermosten about plans for ATR-12, our precision dermatology candidate targeting #NethertonSyndrome - a rare, orphan autosomal recessive disease with no current FDA-approved treatment option. Watch here: https://lnkd.in/eHAt64np #RareDisease #dermatology #biotech
Also from Zacks Small Cap Research and John Vandermosten - Azitra Inc COO Travis Whitfill on ATR-12 https://lnkd.in/eHAt64np
Azitra Inc's COO Travis Whitfill Outlines What's Next for ATR-04 with Senior Analyst John Vandermosten
Thanks John Vandermosten at Zacks Small Cap Research for speaking with Azitra Inc's COO Travis Whitfill about what's next for ATR-04
Azitra Inc's COO Travis Whitfill Outlines What's Next for ATR-04 with Senior Analyst John Vandermosten
Azitra to Present at Microbiome Times Partnering Forum #dermatology #precisionderm #biotech https://lnkd.in/ejtfxmVg
More from Azitra Inc's Travis Whitfill on the DNA Today Podcast What led you to Co-Found Azitra? What need did you see? Check out the full episode here: https://lnkd.in/epGin9wR
ICYMI - Thanks Kira Dineen, MS, LCGC, CG(ASCP)CM of the DNA Today Podcast for speaking with Azitra Inc's COO Travis Whitfill - discussing our approach to #PrecisionDermatology powered by microbial & genetic engineering - Check out the full episode here: https://lnkd.in/etiCMG4t
More from our announcement yesterday - "Our lead product, ATR-12, is an engineered strain of?S. epidermidis?designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. In?August 2024, we initiated a Phase 1b clinical trial investigating ATR-12 in adult Netherton syndrome patients to assess multiple safety, tolerability, and efficacy endpoints. Initial safety data from this trial is expected in the first half of 2025 with topline results by year-end 2025." #NethertonSyndrome #biotech #dermatology $AZTR https://lnkd.in/esdb4Syn
More from today's announcement - We look forward to capitalizing on multiple value-building milestones during '25, including clinical data from our ATR-12 program. These events are expected to provide key inflection points for @azitrainc & investors throughout the year. #biotech #raredisease #PrecisionDerm $AZTR https://lnkd.in/esdb4Syn